VCYT Stock Cash Flow Statements

Veracyte Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Veracyte Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-06-30	2014-03-31

operating activities
net income	-980,000	7,047,000	5,113,000	15,155,000	5,734,000	-1,864,000	-28,293,000	-29,618,000	-8,402,000	-8,091,000	-3,844,000	-8,723,000	-9,532,000	-14,461,000	-10,528,000	-14,129,000	-9,038,000	-41,868,000	-8,044,000	-4,124,000	-11,025,000	-11,716,000	-7,458,000	-730,000	-2,494,000	-1,917,000	-3,105,000	-4,469,000	-6,248,000	-9,177,000	-8,439,000	-7,049,000	-7,298,000	-8,217,000	-4,403,000	-5,637,000	-11,243,000	-10,075,000	-8,945,000	-9,136,000	-7,610,000	-6,655,000	-6,674,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	5,489,000	5,362,000	6,253,000	5,878,000	5,738,000	5,590,000	6,336,000	7,323,000	6,859,000	6,670,000	6,556,000	6,324,000	6,492,000	6,556,000	6,404,000	6,139,000	4,500,000	2,550,000	2,025,000	1,990,000	1,957,000	1,972,000	1,281,000	967,000	924,000	945,000	970,000	981,000	989,000	980,000	1,002,000	993,000	944,000	902,000	909,000	899,000	941,000	762,000	646,000	644,000	352,000	277,000	264,000
loss on disposal of property, plant and equipment			71,000	63,000	38,000	30,000		0	15,000	121,000
stock-based compensation	10,985,000	10,958,000	9,629,000	8,747,000	9,854,000	8,019,000	7,512,000	7,263,000	10,381,000	7,985,000	6,867,000	7,283,000	5,939,000	6,645,000	6,732,000	7,868,000	4,064,000	3,855,000	3,641,000	3,089,000	3,360,000	2,905,000	2,842,000	2,640,000	2,566,000	1,759,000	1,533,000	1,519,000	1,731,000	1,175,000	1,792,000	1,611,000	1,642,000	1,572,000	1,633,000	1,572,000	1,677,000	1,496,000	1,474,000	1,489,000	1,223,000	875,000	492,000
deferred income taxes	59,000	15,000	-243,000	-13,000	143,000	-120,000	-2,996,000	-968,000
noncash lease expense	696,000	904,000	1,327,000	1,341,000	1,148,000	1,139,000	1,028,000	1,153,000	1,074,000	903,000	833,000	849,000	1,051,000	587,000	66,000	681,000	627,000	258,000	250,000	245,000	237,000	232,000
revaluation of acquisition-related contingent consideration	-925,000	-1,954,000	925,000	379,000	858,000	5,000	117,000	-5,156,000	141,000	-485,000	234,000	-32,000	-79,000	31,000	507,000	56,000	55,000	192,000	1,174,000	472,000	344,000	-484,000
effect of foreign currency on operations	-3,465,000	-1,585,000	2,895,000	-1,681,000	259,000	637,000	-1,753,000	824,000	57,000	-224,000	-1,041,000	847,000	585,000	131,000	-390,000	-265,000	1,784,000	82,000	-17,000
impairment loss			2,754,000	185,000	0	429,000	32,039,000	34,900,000	0	1,410,000
changes in operating assets and liabilities:
accounts receivable	2,770,000	-7,053,000	1,991,000	1,690,000	-3,627,000	-6,459,000	-763,000	2,861,000	3,091,000	-1,302,000	-139,000	-1,420,000	639,000	-3,575,000	-2,286,000	428,000	-2,965,000	-3,748,000	-787,000	-2,281,000	3,785,000	238,000	4,284,000	-3,987,000	-3,011,000	-3,447,000	-906,000	744,000	192,000	-482,000	-1,081,000	-608,000	-1,902,000	-369,000	-2,444,000	-2,925,000	-159,000	207,000			466,000
supplies and inventory	-565,000	-2,298,000	-1,696,000	-909,000	-963,000	-2,303,000	-58,000	-4,418,000	1,727,000	1,055,000	-170,000	813,000	-2,453,000	-1,201,000
prepaid expenses and other current assets	-2,532,000	-2,928,000	-1,445,000	2,332,000	555,000	-2,738,000	1,120,000	952,000	534,000	-3,064,000	1,415,000	1,805,000	309,000	-2,139,000	-1,411,000	-617,000	-1,420,000	132,000	-47,000	-259,000	154,000	-818,000	-31,000	377,000	-181,000	-11,000															38,000
other assets	-629,000	-760,000	134,000	-497,000	-1,472,000	259,000	-172,000	462,000	-557,000	-491,000	-3,209,000	-124,000	-167,000	451,000	-569,000	383,000	28,000	-58,000	-97,000	-32,000	31,000	135,000	-209,000	-167,000	-12,000	37,000	-249,000	-239,000	-132,000	-140,000	-148,000			7,000	69,000	-31,000
operating lease liabilities	-609,000	-577,000		-1,483,000	-1,393,000	-1,053,000		-1,134,000	-1,141,000	-950,000		-890,000	-1,083,000	-597,000
accounts payable	-4,007,000	7,120,000	-1,355,000	-1,244,000	-162,000	-1,544,000	-319,000	-607,000	-1,220,000	2,012,000	477,000	1,048,000	-413,000	-960,000	1,283,000	1,114,000	827,000	1,931,000	1,245,000	-656,000	-5,328,000	5,450,000	-2,646,000	759,000	20,000	1,726,000	1,068,000	-724,000	-1,402,000	-510,000	837,000	625,000	-262,000	528,000	-1,054,000	418,000	-1,106,000	301,000				1,332,000	2,045,000
accrued liabilities and deferred revenue	6,798,000	-8,889,000	-351,000	20,000	12,865,000	-8,993,000	2,724,000	334,000	3,987,000	-7,721,000	2,106,000	-728,000	-4,908,000	-390,000	11,096,000	-1,441,000	4,532,000	238,000
net cash from operating activities	33,605,000	5,362,000	24,524,000	29,963,000	29,575,000	-8,966,000	15,552,000	14,171,000	16,671,000	-2,172,000	9,744,000	7,026,000	-363,000	-8,872,000	8,446,000	-1,393,000	1,887,000	-40,561,000	2,261,000	1,752,000	-8,423,000	-5,301,000	1,790,000	-1,556,000	-2,455,000	-1,011,000	-1,226,000	-1,783,000	-3,099,000	-7,413,000	-5,816,000	-5,103,000	-4,910,000	-8,086,000	-4,232,000	-7,438,000
capex	-1,758,000	-842,000	-4,141,000	-3,581,000	-2,633,000	-380,000	-2,497,000	-2,488,000	-5,183,000	631,000	-1,872,000	-1,768,000	-2,783,000	-2,111,000	-841,000	-2,800,000	-865,000	-839,000	-888,000	-635,000	-649,000	-552,000	-1,100,000	-232,000	-659,000	-670,000	-204,000	-659,000	-534,000	-171,000	-446,000	-727,000	-113,000	-615,000	-450,000	-173,000
free cash flows	31,847,000	4,520,000	20,383,000	26,382,000	26,942,000	-9,346,000	13,055,000	11,683,000	11,488,000	-1,541,000	7,872,000	5,258,000	-3,146,000	-10,983,000	7,605,000	-4,193,000	1,022,000	-41,400,000	1,373,000	1,117,000	-9,072,000	-5,853,000	690,000	-1,788,000	-3,114,000	-1,681,000	-1,430,000	-2,442,000	-3,633,000	-7,584,000	-6,262,000	-5,830,000	-5,023,000	-8,701,000	-4,682,000	-7,611,000
investing activities
acquisition of c2i, net of cash acquired			0	0	0	5,012,000
purchase of short-term investments	-49,999,000	-49,999,000					0	0	0	-19,700,000	-24,547,000	0
proceeds from maturity of short-term investments							0	0	0	5,000,000	-15,000	10,521,000
purchases of property, plant and equipment	-1,286,000	-1,819,000	-4,141,000	-2,242,000	-2,770,000	-2,134,000	-2,497,000	-2,802,000	-3,669,000	-993,000
net cash from investing activities	-224,000	-51,818,000	-54,141,000	-2,242,000	-2,770,000	2,878,000	-2,497,000	-2,802,000	-3,669,000	24,080,000	-26,434,000	8,807,000	-9,307,000	-2,453,000	385,000	-165,457,000	1,473,000	-575,607,000	-888,000	-1,635,000	-649,000	-665,000	-41,100,000	-226,000	-658,000	-749,000	-454,000	-659,000	-534,000	-227,000	-300,000	-607,000	-113,000	-175,000	-450,000	-173,000
financing activities
payment of taxes on vested restricted stock units	-2,380,000	-9,451,000	-3,274,000	-2,180,000	-1,303,000	-3,832,000	-1,127,000	-2,446,000	-891,000	-2,277,000	-528,000	-774,000	-418,000	-1,447,000	-722,000	-823,000	-710,000	-6,774,000	-684,000	-483,000	-374,000	-2,304,000
proceeds from the exercise of common stock options and employee stock purchases	1,814,000	2,967,000	3,264,000	12,469,000	1,292,000	2,968,000	1,772,000	2,556,000	1,288,000	3,962,000	1,808,000	2,257,000	340,000	3,537,000	895,000	4,038,000	2,630,000	3,965,000	3,595,000	4,265,000	3,764,000	2,085,000	3,044,000	4,874,000	2,548,000	4,181,000	1,905,000	1,564,000	312,000	569,000	923,000	511,000	49,000	414,000	253,000	317,000	13,000	633,000
net cash from financing activities	-566,000	-6,484,000	-4,510,000	10,289,000	-11,000	-864,000	645,000	110,000	397,000	1,685,000	93,000	1,486,000	-75,000	1,990,000	173,000	3,215,000	1,920,000	591,012,000	2,911,000	197,513,000	3,390,000	-219,000	2,965,000	4,797,000	127,919,000	-8,394,000	1,829,000	56,530,000	239,000	901,000	-1,188,000	442,000	-20,000	548,000	32,202,000	317,000	-135,000	19,945,000	-4,000	37,657,000	92,000
increase in cash, cash equivalents and restricted cash			-34,127,000	38,010,000	26,794,000	-6,952,000	13,700,000	11,479,000	13,399,000	23,593,000					9,004,000
effect of foreign currency on cash, cash equivalents and restricted cash	573,000	74,000	-401,000	146,000	-61,000	-108,000	297,000	-177,000	-7,000	50,000	732,000	-654,000	-423,000	-247,000	164,000	119,000
net increase in cash, cash equivalents and restricted cash			-34,528,000	38,156,000	26,733,000	-7,060,000	13,997,000	11,302,000	13,392,000	23,643,000					9,168,000				4,284,000	197,630,000			-36,345,000	3,015,000			149,000
cash, cash equivalents and restricted cash at beginning of period	0	240,631,000		0	0	217,330,000		0	0	154,996,000		0	0	173,946,000		0	0	349,967,000		0	0	159,920,000		0	0	78,598,000		0	0	34,494,000
cash, cash equivalents and restricted cash at end of period	33,388,000	187,765,000		38,156,000	26,733,000	210,270,000		11,302,000	13,392,000	178,639,000		16,665,000	-10,168,000	164,364,000		-163,516,000	3,483,000	324,811,000		197,630,000	-5,682,000	153,735,000		3,015,000	124,806,000	68,444,000		54,088,000	-3,394,000	27,755,000
supplementary cash flow information:
purchases of property, plant and equipment included in accounts payable and accrued liability	-472,000	977,000		-1,339,000	137,000	1,754,000		314,000	-1,514,000	1,624,000
cash paid for tax	1,432,000	121,000	1,031,000	1,188,000			428,000				140,000	366,000
decrease in cash, cash equivalents and restricted cash		-52,940,000										17,319,000	-9,745,000	-9,335,000
net decrease in cash, cash equivalents and restricted cash		-52,866,000										16,665,000	-10,168,000	-9,582,000			3,483,000	-25,156,000				-6,185,000				-10,154,000			-3,394,000	-6,739,000
interest on end-of-term debt obligation											0	54,000	54,000	53,000	55,000	54,000	54,000	53,000	54,000	55,000	53,000	54,000		54,000	56,000	64,000		81,000	79,000	70,000
operating lease liability															-84,000	-693,000	-644,000	-373,000	-367,000	-358,000	-351,000	-331,000
proceeds from sale of short-term investments							0	0	0	39,773,000
payment of contingent consideration for acquisition
payment of long-term debt											-1,187,000	3,000	3,000	-100,000					0				0	0	-12,400,000	-12,500,000									0	0
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
supplementary cash flow information of non-cash investing and financing activities:
purchases of property and equipment included in accounts payable and accrued liabilities																										95,000	250,000			56,000	-146,000						-381,000	423,000
cash paid for interest on debt
loss on disposal of property and equipment											134,000																								0	0
acquisition of decipher biosciences, net of cash acquired															0
acquisition of haliodx, net of cash acquired															1,226,000
proceeds from sale of equity securities															0	0
proceeds from issuance of common stock in a public offering, net of issuance costs
shares issued for purchase consideration for a business combination
benefit from income taxes											403,000	-152,000	-115,000	-3,000	-961,000	-1,350,000	-152,000	-3,795,000
write-down of excess supplies																			0	0	0	1,088,000
purchase of equity securities																			0
purchases of property and equipment											-1,872,000	-1,714,000	-2,510,000	-2,453,000	-841,000	-1,812,000	-1,527,000	-1,196,000	-888,000	-635,000	-649,000	-665,000	-1,100,000	-232,000	-659,000	-765,000	-454,000	-659,000	-534,000	-227,000	-300,000	-727,000	-113,000	-615,000	-450,000	-173,000
impairment of intangible assets												0
proceeds from the issuance of common stock in a public offering, net of issuance costs																0	0	593,821,000
purchases of property and equipment included in accounts payable and accrued liability												-54,000	-273,000	342,000		-988,000	662,000	357,000				113,000
interest paid on debt																0				0	2,000	1,000		11,000	91,000	228,000		494,000	385,000	356,000
issuance of common stock for acquisition of haliodx
gain on disposal of property and equipment																								-6,000	-1,000	-16,000
amortization and write-off of debt discount and issuance costs																															393,000	26,000	27,000	26,000		27,000	27,000	92,000
supplies															-1,468,000	379,000	-365,000	-10,000	-201,000	2,585,000	-947,000	-376,000	-198,000	-1,504,000	-1,336,000	-366,000	61,000
acquisition of nanostring diagnostics platform
proceeds from the sale of property and equipment
payment of financial lease liability
deferred purchase consideration for a business combination
acquisition of business, net of cash acquired																	0	-574,411,000
other income																											0	0	0	-93,000
accrued liabilities, deferred revenue and deferred rent
cash paid for acquisition
proceeds from legal settlement regarding short-swing profits																											0	0	0	403,000
amortization of debt issuance costs																								0	75,000	8,000		8,000	8,000	8,000
accrued liabilities																				1,043,000	-693,000	-3,650,000
proceeds from disposal of property and equipment																								6,000	1,000	16,000
proceeds from the issuance of common stock in a public offering
payment of finance lease liability																								-77,000	-77,000	-75,000
(gain) loss on disposal of property and equipment
interest on end-of-term debt obligation and prepayment penalty
right-of-use assets - operating lease and operating lease liability																							-100,000	102,000	-93,000	-80,000
accrued liabilities and deferred rent																							3,970,000	-61,000	1,032,000	287,000	-110,000	767,000	-161,000	228,000	38,000	-429,000	1,551,000	-2,323,000	1,542,000	-1,803,000
proceeds from the issuance of long-term debt, net of debt issuance costs																																			0	0	-148,000	24,600,000
payment of end-of-term debt obligation and prepayment penalty																																			0	0
operating lease liability arising from obtaining right-of-use assets - operating lease at beginning of period																							0
cash and cash equivalents
restricted cash
total cash, cash equivalents and restricted cash
proceeds from the issuance of common stock in a public offering, net of costs																								0								0	0	200,000
operating lease liability arising from obtaining right-of-use assets - operating lease																									0	14,118,000
purchases of property and equipment included in accounts payable
bad debt expense																																			0	0	2,000	66,000	26,000	32,000	22,000	11,000	28,000
genzyme co-promotion fee amortization																																			0	-227,000
conversion of accrued interest to long-term debt																																			0	193,000
payment of capital lease liability																											-75,000	-73,000	-73,000	-71,000	-70,000	-69,000	-69,000	-66,000
net receivable for reimbursement of public offering issuance costs
prepaid expenses and current other assets																												-37,000	337,000	-239,000	-247,000	215,000	269,000	-244,000	-452,000	-10,000						-370,000	463,000
proceeds from sale of property and equipment																																0	0	440,000
supplies inventory																													1,508,000	767,000	-1,564,000	-443,000	126,000	32,000	-59,000	86,000	150,000	115,000
change in restricted cash																															0				0	0					70,000
proceeds from issuance of common stock in a private placement, net of issuance costs
payment of deferred stock offering costs
net increase in cash and cash equivalents																																		-7,713,000	27,520,000	-7,294,000	-8,463,000	8,372,000	-4,929,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
conversion of accrued interest on long-term debt
interest on debt balloon payment and prepayment penalty																																			0	0	0	206,000
net decrease in cash and cash equivalents																																-5,268,000
cash and cash equivalents at beginning of period																																0	0	59,219,000	0	0	0	39,084,000	0	0	35,014,000	0	71,220,000
cash and cash equivalents at end of period																																-5,268,000	-5,043,000	51,506,000	27,520,000	-7,294,000	-8,463,000	47,456,000	-4,929,000	25,247,000	25,798,000	-6,239,000	64,237,000
unpaid deferred stock offering
amortization of debt discount and issuance costs																																							11,000	12,000	11,000	28,000	26,000
cash remitted for acquisition, net of cash received
commissions and issuance costs relating to initial public offering
fair value of common stock issued for acquisition
non-cash issuance of long-term debt
non-cash repayment of long-term debt
issuance of common stock from the non-cash exercise of common stock warrants
proceeds from the issuance of common stock in a private placement, net of costs
unpaid deferred debt issuance costs																																						148,000
interest on debt balloon payment																																							20,000	20,000	19,000	20,000	20,000
proceeds from issuance of common stock in a private placement, net of costs																																							0
commissions and issuance costs relating to the initial public offering
proceeds from the exercise of common stock options																																							193,000	399,000	92,000	448,000	27,000
unpaid deferred stock offering costs
change in value of preferred stock liability
proceeds from issuance of long-term debt, net of debt issuance costs
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
payment of convertible preferred stock issuance costs
equity-based compensation
change in value of preferred stock warrant liability
accounts receivables
deferred genzyme co-promotion fee

We provide you with 20 years of cash flow statements for Veracyte stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Veracyte stock. Explore the full financial landscape of Veracyte stock with our expertly curated income statements.

The information provided in this report about Veracyte stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.